复方保和丸治疗糖尿病胃轻瘫的疗效

目的 了解复方保和丸对糖尿病胃轻瘫的疗效。方法 治疗组40例,并设西药治病组32例予以对照。结果 治疗组的症状、血脂、胃电图在治疗前后都有显差异,而对照组则无显差异。结论 应用复方保和丸临床疗效明显,没有副作用。     

上海社区糖尿病前期及糖尿病人群视网膜病变患病率及相关危险因素分析

Objective To determine the prevalence and risk factors of diabetic retinopathy (DR) in the Diabetes Mellitus (DM) and impaired glucose regulation (IGR) population in Shanghai Community. Methods DR screening after the epidemiologic study of metabolic syndrome in Huayang and Canyang Community , Shanghai was conducted among 1300 patients with DM or IGR during June 2005 and March 2006, Digital non-mydriatic fundus photography was performed for each eye in all subjects. Other factors, including diabetes related history, BMI, WHR, fasting plasma glucose, HbAlc, serum lipid and blood pressure were also assessed. 642 patients,312 males and 330 females, aged 65 ± 13, with complete data were enrolled into the analysis. Results The prevalence of DR was 19. 9% in the diabetic population, and the prevalence of mild, moderate, severe non-proliferative retinopathy and proliferative retinopathy was 12. 0%, 5. 1%, 2. 3% and 0. 5%, respectively; the prevalence of DR in IGR reached 8. 0%. Logistic regression analysis revealed that HbA1c level and diabetes duration were both independently associated with diabetic retinopathy. Conclusion The prevalence of DR was high in both DM and IGR population. Bad blood glucose control and long diabetes duration both increased occurrence of DR.     

尿白蛋白排泄率对糖尿病肾病的早期诊断意义

尿白蛋白排泄率对糖尿病肾病的早期诊断意义。方法：８６例糖尿病患者留取过夜１２ｈ尿,用放免法测定白蛋白的含量。结果：病程５年以下组测得ＵＡＥ值产高８例占１８．２％。５年以上组有１８例,升高占４２．９％。     

益肾糖泰颗粒对糖尿病大鼠肾脏病变的影响

目的：探索纯中药制剂益肾糖泰颗粒对糖尿病肾病（ＤＮ）的治疗机理。方法：观察治疗１周、１３周、２６周时益肾糖颗粒对糖尿病肾病大鼠模型的血糖、糖基化血红蛋白、肾重／体重、肾功及肾小球形态变化等。结果：益肾糖泰颗粒有有效改善实验性ＤＮ大鼠异常升高的血糖、ＨｂＡ１ｃ水平,能有效控制糖尿病肾脏的肥大,明显改善实验性ＤＮ大鼠肾脏功能的异常,光镜、电镜和计算机图像分析证实益肾糖泰颗粒能明显改善肾小球组织形态的异     

针刺对糖尿病视网膜病变免疫调节机理的研究

目的：探讨针刺治疗糖尿病视网膜病变的机理,并加以论证,为其临床应用提供理论依据。方法：选择大鼠建立糖尿病视网膜病变动物模型,分别以针刺治疗及胰岛素治疗,并设正常对照组及模型对照组,于３个月及６个月取大鼠血清及视网膜检测ＩＬ－２和ＴＮＦ及电镜检察。结果：各时段ＩＬ－２针刺及胰岛素治疗组明显高于模型对照组：ＴＮＦ明显氏于模型对照组。两与正常对照组无显性差异,针刺后电镜观察视网膜微血管病变得到改善。     

血浆内皮素和非酯化脂肪酸改变与糖尿病视网膜病变的关系

目的：为探讨血浆内皮素（ＥＴ）和非酯化脂肪酸（ＮＥＦＡ）水平与糖尿病视网膜病变（ＤＲ）Ｒ 关系。方法：分组分析了５６例伴和不伴ＤＲ的２型糖尿病（ＤＭ）人血浆ＥＴ和ＮＥＥＡ水平,并与正常人进行了比较。结果：２型ＤＭ病人血浆ＥＴ水平明显高于正常人,伴有ＤＲ组病人又明显高于无ＤＲ的病人。     

中药合剂治疗糖尿病性视网膜病变的临床观察

目的:探讨治疗糖尿病性视网膜病变(DR)的有效方药。方法:用益气养阴化瘀合剂治疗DR30例,达美康对照治疗20例;以视力、眼底病理改善及临床症状和血糖的变化为主要观察指标评定疗效。结果:中药合剂总有效率优于对照组(P<0.01);其中对全身症状、血脂、血液流变学的改善,以及视力提高和眼底病变的改善作用,治疗组均明显优于西药对照组(P<0.05或P<0.01)。结论:益气养阴化瘀合剂能有效改善全身血液高糖、高凝、高粘及高脂状态,具有较好的促进视网膜出血、渗出的吸收及提高视力的作用。     

山药对糖尿病小鼠组织丙二醛含量的影响

目的：观察山药对糖尿病小鼠组织丙二醛（ ＭＤＡ） 含量的影响。方法：采用四氧嘧啶制作糖尿病小鼠模型,并以优降糖作阳性对照,连续２１ 天用不同剂量山药灌胃治疗,比较各组心脏、肝脏、肾脏和胰脏过氧化脂质的终末代谢产物ＭＤＡ 含量。结果：①对照组四器官ＭＤＡ显著高于正常组（Ｐ＜ ０ ．０１ 或Ｐ＜ ０ ．００１） ;②剂量在６ ．００ｇ／ｋｇ·ｄ－ １ 以上山药各治疗组四器官ＭＤＡ显著低于对照组（Ｐ＜ ０ ．０５ 或Ｐ＜ ０．００１） ;③与优降糖组比,除肝脏ＭＤＡ 较高外（Ｐ＜ ０．００１） ,中、大剂量山药组心、胰、肾组织ＭＤＡ 较低（Ｐ＜ ０ ．０５ 或Ｐ＜ ０ ．００１） 。结论：山药能明显降低糖尿病小鼠组织内过氧化脂质含量,尤其对心组织作用最强,其次为胰、肾和肝组织,而优降糖对胰组织过氧化脂质无明显影响。     

The pyridoindole antioxidant stobadine inhibited glycation-induced absorbance and fluorescence changes in albumin

We studied the effect of the pyridoindole antioxidant stobadine on glycation-induced absorbance and fluorescence changes in bovine serum albumin (BSA), used as a model protein. Incubation of BSA (4 mg/ml) with glucose (100–400 mM) in 0.12 M phosphate buffer, pH 7.4, in the presence of 100 M Cu²⁺ at 37°C resulted in a time-dependent increase of absorbance (320 nm) and fluorescence (excitation 350 nm, emission 415 nm). The process was found to be dependent on the presence of oxygen and transition metal ions, but equimolar iron could not fully substitute for the activity of copper. The glucose-induced chromo- and fluorophore formation was reduced significantly by stobadine. For 200 mM glucose, in 7- and 14-day incubations, 51%–60% inhibition was obtained at a stobadine concentration of 0.1 mM, and the effect leveled off at higher concentrations of the drug. No inhibition was observed withN-acetyl stobadine, a derivative with restricted antioxidant activity. Since stobadine did not affect the Amadori product formation determined by the thiobarbituric acid (TBA) method as 5-hydroxymethyl furfural (5-HMF) released in boiling oxalic acid, the inhibitory action of stobadine may be explained by its interference with metal-catalyzed oxidation reactions following after the glycation step. The results obtained suggest that antioxidant therapy could be used to limit the damage from adverse glycation-induced processes in diabetes mellitus.